Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe + Simvastatin in HeFH (ENHANCE)
NCT00552097Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Jun 2002
- Primary completion
- Apr 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ezetimibe in heterozygous familial hypercholesterolemia (HeFH), sponsored by Organon & Co. Primary endpoint: Change in ultrasound-determined average carotid artery intima-media thickness at 24 months. Started Jun 2002; status: completed.
02
Drugs
ezetimibe
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT00552097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00552097.